美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Electra Therapeutics INC

13.25

-1.7500-11.67%

盤後：13.520.2700+2.04%19:59 EDT

成交量：512.43萬

成交額：7,457.47萬

市值：8.10億

市盈率：- -

高：15.50

開：15.00

低：13.25

收：15.00

52周最高：15.50

52周最低：13.25

股本：6,110.03萬

流通股本：2,166.67萬

量比：- -

換手率：23.65%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Electra Therapeutics INC

交易所：

NASDAQ

成立時間：

2018

員工人數：

- -

公司地址：

230 E Grand Avenue,Suite S-100,South San Francisco,California,United States

官網：

http://electra-therapeutics.com

郵編：

94080

電話：

傳真：

- -

簡介：

Electra Therapeutics, Inc.成立於2018年，是一家處於臨床後期階段的生物製藥公司，致力於開發用於治療免疫介導疾病和癌症的新型精準藥物。該公司的研發策略靶向信號調節蛋白（SIRP），這是一類細胞表面受體，其表達僅限於特定的免疫細胞群，並在激活后表達上調。SIRP能夠選擇性地清除致病細胞，同時保留正常的免疫功能。該公司的主要候選產品是ipsoprubart，一種新型泛SIRP單克隆抗體，旨在選擇性地清除病理性髓系細胞和T細胞。此外，該公司還在推進ELA822的研發，ELA822是一種新型SIRPg特異性單克隆抗體，旨在選擇性地清除活化的T細胞，具有治療慢性T細胞介導的免疫和炎症性疾病的潛在應用價值。

董事

名稱

職位

Nancy Stagliano

Chairman of the Board and Director

Quehuong Dong

Chief Executive Officer and Director and President

Beth Seidenberg

Director

Carl L. Gordon

Director

Matthew Fust

Director

Thomas Geninatti

Director

股東

名稱

職位

Quehuong Dong

Chief Executive Officer and Director and President

Chris Clark

Chief Financial Officer

Gary S. Koe

Chief Technical Officer

Graham Parry

Chief Scientific Officer

Kim Hien Dao

Chief Medical Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/ETRA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ETRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ETRA\",,,,,undefined,":{"symbol":"ETRA","market":"US","secType":"STK","nameCN":"Electra Therapeutics INC","latestPrice":13.25,"timestamp":1789761600000,"preClose":15,"halted":0,"volume":5124319,"hourTrading":{"tag":"盘后","latestPrice":13.52,"preClose":13.25,"latestTime":"19:59 EDT","volume":17079,"amount":234585.3427,"timestamp":1789775990519,"change":0.27,"changeRate":0.020377,"amplitude":0.037736},"delay":0,"changeRate":-0.11666666666666667,"floatShares":21666667,"shares":61100300,"eps":0,"marketStatus":"已收盤","change":-1.75,"latestTime":"09-18 16:00:00 EDT","open":15,"high":15.5,"low":13.25,"amount":74574706.341624,"amplitude":0.15,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":5,"adr":0,"listingDate":1789704000000,"exchange":"NASDAQ","adjPreClose":15,"postHourTrading":{"tag":"盘后","latestPrice":13.52,"preClose":13.25,"latestTime":"19:59 EDT","volume":17079,"amount":234585.3427,"timestamp":1789775990519,"change":0.27,"changeRate":0.020377,"amplitude":0.037736},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ETRA\",,,,,undefined,":{"symbol":"ETRA","floatShares":21666667,"roa":"--","roe":"--","lyrEps":0,"shares":61100300,"dividePrice":0,"high":15.5,"amplitude":0.15,"preClose":15,"low":13.25,"week52Low":13.25,"pbRate":"--","week52High":15.5,"institutionHeld":0,"latestPrice":13.25,"eps":0,"divideRate":0,"volume":5124319,"delay":0,"ttmEps":0,"open":15,"prevYearClose":15,"prevWeekClose":15,"prevMonthClose":15,"prevQuarterClose":15,"fiveDayClose":15,"twentyDayClose":15,"sixtyDayClose":15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ETRA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ETRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ETRA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1771786528,"yearFounded":2018,"address":"230 E Grand Avenue,Suite S-100,South San Francisco,California,United States","zipCode":"94080","officePhone":"(888) 743-2290"},"stockCompanyDetail":{"websiteUrl":"http://electra-therapeutics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1758},{"period":"1year","weight":0.1569},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Electra Therapeutics, Inc.成立於2018年，是一家處於臨床後期階段的生物製藥公司，致力於開發用於治療免疫介導疾病和癌症的新型精準藥物。該公司的研發策略靶向信號調節蛋白（SIRP），這是一類細胞表面受體，其表達僅限於特定的免疫細胞群，並在激活后表達上調。SIRP能夠選擇性地清除致病細胞，同時保留正常的免疫功能。該公司的主要候選產品是ipsoprubart，一種新型泛SIRP單克隆抗體，旨在選擇性地清除病理性髓系細胞和T細胞。此外，該公司還在推進ELA822的研發，ELA822是一種新型SIRPg特異性單克隆抗體，旨在選擇性地清除活化的T細胞，具有治療慢性T細胞介導的免疫和炎症性疾病的潛在應用價值。","exchange":"NASDAQ","name":"Electra Therapeutics INC","nameEN":"ELECTRA THERAPEUTICS INC"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ETRA\",market:\"US\",,,undefined,":{"directors":[{"name":"Nancy Stagliano","position":"Chairman of the Board and Director"},{"name":"Quehuong Dong","position":"Chief Executive Officer and Director and President"},{"name":"Beth Seidenberg","position":"Director"},{"name":"Carl L. Gordon","position":"Director"},{"name":"Matthew Fust","position":"Director"},{"name":"Thomas Geninatti","position":"Director"}],"executives":[{"name":"Quehuong Dong","position":"Chief Executive Officer and Director and President"},{"name":"Chris Clark","position":"Chief Financial Officer"},{"name":"Gary S. Koe","position":"Chief Technical Officer"},{"name":"Graham Parry","position":"Chief Scientific Officer"},{"name":"Kim Hien Dao","position":"Chief Medical Officer"}]}}}